These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 9748527

  • 1. Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine.
    López-Baena M, Mateos S, Piñero J, Trinidad Ortiz, Cortés F.
    Mutat Res; 1998 Oct 12; 421(1):109-16. PubMed ID: 9748527
    [Abstract] [Full Text] [Related]

  • 2. Synergistic effect of inhibitors of topoisomerase I and II on chromosome damage and cell killing in cultured Chinese hamster ovary cells.
    Cortés F, Piñero J.
    Cancer Chemother Pharmacol; 1994 Oct 12; 34(5):411-5. PubMed ID: 8070008
    [Abstract] [Full Text] [Related]

  • 3. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S, Riou G.
    Biochem Pharmacol; 1994 Aug 30; 48(5):975-84. PubMed ID: 8093110
    [Abstract] [Full Text] [Related]

  • 4. Importance of replication fork progression for the induction of chromosome damage and SCE by inhibitors of DNA topoisomerases.
    Cortés F, Piñero J, Ortiz T.
    Mutat Res; 1993 Oct 30; 303(2):71-6. PubMed ID: 7692280
    [Abstract] [Full Text] [Related]

  • 5. Interaction effects of 5-azacytidine with topoisomerase II inhibitors on CHO cells, as detected by cytogenetic analysis.
    Takahashi-Hyodo SA, Sakamoto-Hojo ET, Takahashi CS.
    Mutat Res; 1999 Dec 16; 431(1):13-23. PubMed ID: 10656482
    [Abstract] [Full Text] [Related]

  • 6. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
    D'Arpa P, Beardmore C, Liu LF.
    Cancer Res; 1990 Nov 01; 50(21):6919-24. PubMed ID: 1698546
    [Abstract] [Full Text] [Related]

  • 7. Cytogenetical characterization of Chinese hamster ovary X-ray-sensitive mutant cells, xrs 5 and xrs 6. IV. Study of chromosomal aberrations and sister-chromatid exchanges by restriction endonucleases and inhibitors of DNA topoisomerase II.
    Darroudi F, Natarajan AT.
    Mutat Res; 1989 Jun 01; 212(2):137-48. PubMed ID: 2543922
    [Abstract] [Full Text] [Related]

  • 8. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH, Andersson BS, Nelson JA.
    Cancer Biochem Biophys; 1990 Jan 01; 11(1):23-30. PubMed ID: 2159843
    [Abstract] [Full Text] [Related]

  • 9. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells.
    Del Bino G, Skierski JS, Darzynkiewicz Z.
    Exp Cell Res; 1991 Aug 01; 195(2):485-91. PubMed ID: 1649059
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. DNA demethylation protects from cleavable complex stabilization and DNA strand breakage induced by the topoisomerase type I inhibitor camptothecin.
    Orta ML, Mateos S, Cortés F.
    Mutagenesis; 2009 May 01; 24(3):237-44. PubMed ID: 19201781
    [Abstract] [Full Text] [Related]

  • 14. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
    Adlakha RC, Ashorn CL, Chan D, Zwelling LA.
    Cancer Res; 1989 Apr 15; 49(8):2052-8. PubMed ID: 2539251
    [Abstract] [Full Text] [Related]

  • 15. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA.
    Lin JH, Castora FJ.
    Arch Biochem Biophys; 1995 Dec 20; 324(2):293-9. PubMed ID: 8554321
    [Abstract] [Full Text] [Related]

  • 16. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
    Kaufmann SH.
    Cancer Res; 1991 Feb 15; 51(4):1129-36. PubMed ID: 1705167
    [Abstract] [Full Text] [Related]

  • 17. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH, Dejligbjerg M, Hansen LT, Grauslund M, Jensen PB, Sehested M.
    BMC Pharmacol; 2004 Dec 02; 4():31. PubMed ID: 15575955
    [Abstract] [Full Text] [Related]

  • 18. Cytogenetic effects of inhibition of topoisomerase I or II activities in the CHO mutant EM9 and its parental line AA8.
    Cortés F, Piñero J, Palitti F.
    Mutat Res; 1993 Aug 02; 288(2):281-9. PubMed ID: 7688089
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
    Nakamura K, Sugumi H, Yamaguchi A, Uenaka T, Kotake Y, Okada T, Kamata J, Niijima J, Nagasu T, Koyanagi N, Yoshino H, Kitoh K, Yoshimatsu K.
    Mol Cancer Ther; 2002 Jan 02; 1(3):169-75. PubMed ID: 12467211
    [Abstract] [Full Text] [Related]

  • 20. The DNA demethylating 5-azaC induces endoreduplication in cultured Chinese hamster cells.
    Mateos S, Domínguez I, Pastor N, Cantero G, Cortés F.
    Mutat Res; 2005 Oct 15; 578(1-2):33-42. PubMed ID: 16202795
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.